1. Introduction {#s0005}
===============

"Coronavirus disease 2019" (COVID-19) is a generally mild but sometimes severe and potentially even life-threatening infection caused by the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2), previously known as "2019 novel coronavirus" (2019-nCoV). Since late December 2019, the SARS-CoV-2 has quickly spread out from its first epicenter, the city of Wuhan, Hubei Province, People\'s Republic of China \[[@bb0005]\], and has shortly become a pandemic \[[@bb0010]\]. Epidemiological data are mainly available for those countries most hardly hit by COVID-19, such as People\'s Republic of China \[[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045]\], Italy \[[@bb0050]\] and the USA \[[@bb0055], [@bb0060], [@bb0065]\]. More limited information is available for countries like Israel. On the other hand, these surveys mainly deal with clinical characteristics of COVID-19 patients, in terms of related risk factors or underlying co-morbidities, whereas unsatisfactory information is provided regarding the therapeutic interventions adopted. Furthermore, these studies are mostly clinical reports, case-series, or are designed as specific cohort studies targeting specific populations, and are not conducted at the level of entire communities, for example exploiting computerized clinical records and similar "real-world data" \[[@bb0070]\]. A notable exception is represented by the report published by the Chinese Center for Disease Control and Prevention, that analyzed the characteristics of 72,314 COVID-19 patients, even though only 62% of the entire sample consisted of confirmed cases \[[@bb0015]\]. Thus, currently available data do not enable to address some crucial research questions, especially in terms of therapeutics \[[@bb0075],[@bb0080]\].

Currently, no effective vaccines or specific drugs exist that can be used to prevent or counteract/mitigate the burden of COVID-19 and so far countries have adopted behavioral, non-pharmacological intervention (NPI)-based strategies, enforcing social distancing, self-isolation, quarantine and even lockdown of entire territories and communities. Since NPIs are resource-consuming, being unfeasible and unsustainable for long periods in the western countries and given that the discovery of new vaccine candidates or new chemical/molecular entities (NCEs/NMEs), the design and the implementation of randomized controlled trials (RCTs) are time-consuming procedures, some scholars are attempting to repurpose already existing compounds.

Hydroxychloroquine is an anti-malarial drug, utilized also for the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and porphyria cutanea tarda patient \[[@bb0085]\]. Colchicine is utilized for the treatment and management of patients with gout and Behçet\'s disease and for the prevention of pericarditis and familial Mediterranean fever (FMF), being preferred over other possible therapeutic options, such as non-steroidal anti-inflammatory drugs (NSAIDs) or steroids \[[@bb0090]\].

Contrasting findings have been reported in the existing scholarly literature concerning potential anti-viral effects of these compounds. As such, in this study, we investigated whether a chronic baseline use of anti-inflammatory medications (namely, hydroxychloroquine and colchicine) could provide a potentially beneficial effect in preventing or, at least partially, mitigating the burden of the SARS-CoV-2 infection. Therefore, for this purpose, we utilized a large Israeli healthcare database.

2. Material and methods {#s0010}
=======================

2.1. Setting and data source {#s0015}
----------------------------

Maccabi Health Services (MHS) is the second largest sick fund in Israel, insuring and providing care to 2.3 million persons. Since 1995, MHS has maintained a computerized database which includes all physicians\' visits, diagnoses, hospitalizations, medications dispensed, all laboratory tests performed and other diagnostic procedures. In the present analysis, we included all individuals tested for SARS-CoV-2. The study protocol was in-depth reviewed and approved by MHS\'s Research Ethics Board.

2.2. Study population {#s0020}
---------------------

In Israel, the first COVID-19 case was confirmed on February 21st 2020 and, since then, the epidemic is on the rise. Using the MHS database, we identified all COVID-19 confirmed cases, defined as positive for SARS-CoV-2 according to the result of the real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR)-based assay of nasal and throat swab specimens between February 23rd 2020 (index case in the MHS database) and March 31st 2020. Subjects negative for SARS-CoV-2 were used as the control group. Criteria for testing were established according to the guidelines published by the Israeli Ministry of Health ("Guidelines for coping with the novel coronavirus", 2020, Ministry of Health, Israel) \[[@bb0085]\], which included an acute febrile illness or respiratory symptoms (cough or shortness of breath) in people returning from abroad travels or who were in close contact with a confirmed or probable COVID-19 case in the last 14 days. The MHS database was also extensively mined to collect all available information on demographics, the most recent documented body mass index (BMI), medical conditions, dispensed and prescribed hydroxychloroquine and colchicine between January 1st 2020 and the date of first SARS-COV-2 test. Furthermore, the socioeconomic status (SES) was computed, defined according to the poverty index of each member as specified during the 2008 National Census, which takes into account several parameters, including household income, education, crowding, material conditions, and car ownership, among others.

2.3. Statistical analysis {#s0025}
-------------------------

After visually inspecting data for potential outliers, descriptive statistics was carried out. Continuous data were expressed as mean ± standard deviation and categorical parameters were computed as percentages, where appropriate. Based on the normality of data distribution, Student\'s *t*-test (or its non-parametric version) and chi-squared test were conducted to compare parameters between COVID-19 positive and negative individuals. Figures with *p*-values equal to or less than 0.05 were considered statistically significant. Statistical analyses were carried out by means of the commercial software "Statistical Package for Social Sciences" (SPSS for Windows, version 24.0, IBM Corp., Armonk, NY, USA).

3. Results {#s0030}
==========

An overall sample of 14,520 subjects were screened for COVID-19. Their characteristics are summarized in [Table 1](#t0005){ref-type="table"} . Mean age of the cohort was 37.3 ± 19.1 years with a slight male predominance (52.6%). Only 1317 (9.07%) resulted positive for COVID-19, approximately 60% of which were males (*p*-value \<.001). The age group distribution was similar among the subjects positive for COVID-19 compared to controls even though the mean age was higher in cases (40.6 ± 19.1 years) versus controls (average age 37.0 ± 19.1 years; *p*-value \<.001). The BMI group distribution differed among cases and controls (p-value \<.001), with the former ones reporting more overweight and obesity than the latter ones. The frequency of all co-morbidities was higher among positive subjects: in more detail, the prevalence rates of diabetes mellitus (DM) (8.7% versus 4.9%, *p* \< .001), chronic kidney disease (7.9% versus 6.2%, *p* = .019) and hypertension (14% versus 10.9%, *p* = .001) were found to be statistically significant and higher among the COVID-19 positive patients. Ischemic heart disease (IHD), instead, was reported in similar percentages by cases and controls (3% versus 2.5%, respectively, *p* = .245). Of note, more cases than controls (27.9% versus 12.7%, *p*-value \<.001) lived in households that were of low SES.Table 1Demographics and co-morbidities of the study population stratified according to SARS-CoV-2 positive and negative subjects.Table 1SARS-CoV-2AllP-valuePositiveNegative*N* = 14,520*n* = 1317n = 13,203Sex, female, n (%)529 (40.2%)7111 (46.1%)7640 (47.4%)\<0.001Age (years), mean (SD)40.6 (19.1)37.0 (19.1)37.3 (19.1)\<0.001Socioeconomic status: Low27.9%12.7%14.1%\<0.001 Medium44.9%50%49.5% High27.2%37.3%36.4%BMI (kg/m2), %: \<2545.7%52.6%52.0%\< 0.001 25--3029.1%24.7%25.1% 30--3514.1%10%10.4% \>355.2%4.6%4.6%IHD, n (%)40 (3%)331 (2.5%)371 (2.6%)0.245DM, n (%)115 (8.7%)642 (4.9%)757 (5.2%)\<0.001CKD, n (%)104 (7.9%)823 (6.2%)927 (6.4%)0.019Hypertension185 (14%)1445 (10.9%)1630 (11.2%)0.001Chronic use of hydroxychloroquine prior to COVID-19 outbreak3 (0.23%)33 (0.25%)36 (0.25%)0.877Chronic use of colchicine prior to COVID-19 outbreak7 (0.53%)64 (0.48%)71 (5%)0.817[^2]

Concerning the baseline treatment, hydroxychloroquine and colchicine were prescribed to subjects with SARS-CoV-2 infection compared to those without in rate of 0.23% versus 0.25% (*p* = .877) and 0.53% versus 0.48% (*p* = .817) of the populations, respectively ([Table 1](#t0005){ref-type="table"}).

4. Discussion {#s0035}
=============

In the present study, we have utilized "real-world data" to explore the associations between subjects positive for SARS-COV-2, different underlying co-morbidities and medications, which were not administered for anti-viral treatment purposes. We demonstrated that some underlying co-morbidities (DM, hypertension, and CKD, but not IHD), high BMI and male gender were associated with a higher susceptibility of contracting SARS-CoV-2 infection.

Our results are in line with a recently published comprehensive meta-analysis pooling together 19 studies (18 from mainland China and one from Australia), the overall sample of which consisted only of confirmed patients according to the procedure of RT-PCR testing \[[@bb0025]\]. More than half (56%) of the patients were males and the major underlying co-morbidities were hypertension (18.6%), cardiovascular disease (14.4%) and DM (11.9%). In a population-based study evaluating the clinical characteristics of 1482 patients hospitalized with COVID-19 in the USA \[[@bb0095]\] the majority of patients were males (54.4%) with a similar pattern of underlying co-morbidities, most commonly hypertension (49.7%), followed by obesity (48.3%), DM (28.3%), and cardiovascular disease (27.8%). More than 70% of patients were older than 50 years. In another cross-sectional study, the same pattern of co-morbidities -- hypertension (18.6%, *p* \< .001), cardiovascular disease (14.4%, p \< .001) and DM (11.9%, p \< .001) -- and male gender predominance (56%, p \< .001) were observed in a population with an average age of 52 years \[[@bb0055]\]. Thus, it is noticeable that underlying co-morbidities and gender are similar among the different populations, but a mean age discrepancy exists between our cohort (average age of 40.6 years) and the other mentioned studies. This discrepancy might be due to the relative high percentage of young population in Israel where the median age in 2020 is 30.5 years, ten years younger than the populations in the USA and mainland China \[[@bb0100]\]. This is even more noticeable in particular settings, such as COVID-19 endemic cities, where population (especially, ultra-orthodox Jewish populations with a high number of children per family) is even younger with respect to the country.

Furthermore, more subjects positive for the COVID-19 infection were of lower SES status compared to controls (27.9% versus 12.7%), and more subjects negative for SARS-CoV-2 were of higher SES compared to positive subject (27.2% versus 36.4%). This is not surprising given the well-known association between low SES and increased risk for infections \[[@bb0105]\]. In the USA, minorities like African Americans and Hispanics have higher rates of mortality compared to the Caucasian population, largely due to SES disparities \[[@bb0110],[@bb0115]\].

Concerning the alleged anti-viral activities of hydroxychloroquine \[[@bb0115]\] and its potential protective role against infections \[[@bb0120]\], the existing scholarly literature reports contrasting findings even though to date no RCT has shown an unequivocal advantage in preventing or improving the major outcomes in COVID-19 patients \[[@bb0125],[@bb0130]\]. Regarding the anti-inflammatory properties of colchicine, results from experimental models found that the NLRP3 inflammasome can be activated and triggered by different SARS-CoV-2 proteins and, subsequently, can take part in the development of the "severe adult respiratory distress syndrome" (ARDS), a complication of the COVID-19 infection \[[@bb0135], [@bb0140], [@bb0145], [@bb0150]\]. As a major inhibitor of the NLRP3 inflammasome \[[@bb0155]\], colchicine could be utilized for the treatment of COVID-19. Currently, three clinical trials are ongoing \[[@bb0135],[@bb0160],[@bb0165]\]. However, in our investigation, we failed to detect a potential benefit of hydroxychloroquine and colchicine. Even though these drugs had not been administered for anti-viral treatment purposes, we were not able to identify the main reason of such an administration. On the other hand, we can assume that patients receiving these drugs suffer from inflammatory diseases such as RA and SLE in the case of hydroxychloroquine \[[@bb0170]\] and FMF and gout in the case of colchicine \[[@bb0175],[@bb0180]\].

Despite the use of a large healthcare database, our study has several limitations that should be properly acknowledged: first, the relatively small number of patients who were documented to be a priori treated. Secondly, the basic methodology of the study, which is based on a computerized database, which might be incomplete. For instance, the duration and the reason of the treatment, as previously mentioned, are lacking. However, this study should be considered as a preliminary, pilot investigation, providing a first glance on the characteristics of patients with SARS-CoV-2 infection in Israel, showing that: 1) the median age of infected individuals is younger than their counterparts around the world, which warrants further research, and 2) that hydroxychloroquine and colchicine apparently provided no protection against the SARS-CoV-2 infection.
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[^2]: BMI-body mass index, IHD- ischemic heart disease, DM -- diabetes mellitus, CKD- chronic kidney disease.
